Controlled, double-blind, randomized trial to assess the efficacy and safety of hydroxychloroquine chemoprophylaxis in SARS CoV2 infection in healthcare personnel in the hospital setting: A structured summary of a study protocol for a randomised controlled trial
Abstract Background SARS-CoV-2 infection presents a high transmission in the group of health professionals in Spain (12-15% infected). Currently there is no accepted chemoprophylaxis but hydroxychloroquine (HDQ) is known to inhibit the coronavirus in vitro. Our hypothesis is that oral administration...
Main Authors: | Antonio Cuadrado-Lavín, José Manuel Olmos, José Manuel Cifrian, Teresa Gimenez, Marco Antonio Gandarillas, Mar García-Saiz, Maria Henar Rebollo, Victor Martínez-Taboada, Marcos López-Hoyos, María Carmen Fariñas, Javier Crespo |
---|---|
Format: | Article |
Language: | English |
Published: |
BMC
2020-06-01
|
Series: | Trials |
Subjects: | |
Online Access: | http://link.springer.com/article/10.1186/s13063-020-04400-4 |
Similar Items
-
Withania somnifera as a safer option to hydroxychloroquine in the chemoprophylaxis of COVID-19: Results of interim analysis
by: Arvind Chopra, et al.
Published: (2021-11-01) -
Adverse drug reaction profile of prophylactic hydroxychloroquine for COVID-19 among doctors
by: Rajesh K Kulkarni, et al.
Published: (2020-01-01) -
Chemoprophylaxis of leprosy with rifampicin in contacts of multibacillary patients: study protocol for a randomized controlled trial
by: Daiane Santos dos Santos, et al.
Published: (2018-04-01) -
Waiting for Godot: A cross sectional survey based analysis of the hydroxychloroquine prophylaxis strategy against COVID-19 in India
by: Merlin Moni, et al.
Published: (2020-12-01) -
Safety and tolerability of hydroxychloroquine in health care workers and first responders for the prevention of COVID-19: WHIP COVID-19 Study
by: John E. McKinnon, et al.
Published: (2022-03-01)